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We read with interest the paper from Sadeghi et al.1
recently published in your journal. The authors studied
the effect of administration order of BU and CY as a
conditioning regimen for hematopoietic SCT (HSCT) in
a mouse model. They showed that inverting the order of
BU–CY to CY–BU not only decreased conditioning-
related toxicity signiﬁcantly, but also allowed the same
level of donor hematopoietic stem cell (HSC) engraftment.
These data support earlier studies showing a potential
beneﬁt of CY–BU in animal models, and do encourage
further investigation in humans.2
To test the possible effect on liver toxicity and clinical
outcome of this approach, we started a clinical trial using
CY–BU as a myeloablative conditioning regimen for
HSCT in 2005.
The results were compared with those of a historical
control of patients treated with a conventional conditioning
regimen of BU–CY.
From September 2005 to November 2006, 11 patients
were subjected to HSCT (nine allogeneic and
two autologous) at the University Hospital (Federal
University of Sa˜o Paulo/UNIFESP), Sa˜o Paulo, Brazil.
Patients’ characteristics are shown in Table 1. There
was one case of aggressive non-Hodgkin’s lymphoma,
three cases of myelodysplastic syndrome, ﬁve cases of
acute leukemia, one case of chronic myeloid leukemia and
one case of severe aplastic anemia. The conditioning
regimen consisted of CY 60mg/m2/kg on days 7 and 6
followed by oral BU 1mg/kg administered every 6 h
(total of 16 doses) on days 5 to 2. As post-grafting
immunosuppression, all patients received a short course
of MTX associated with CYA from day 1. The
source of donor HSCs was peripheral G-CSF mobilized
blood in seven patients and BM in four patients (one
case of severe aplastic anemia, one case of CML and
two cases of autologous patients). HSC were infused
on day 0. All patients received as infection prophylaxis
ﬂuconazol, ciproﬂoxacin, acyclovir and sulfame-
toxazol-trimetropin. Patients also received phenytoin
for BU-related central nervous system toxicity. The
historical control group consisted of 51 consecutive
patients, treated in the same institution, from January
2001 to July 2005, using the same protocol of immunosup-
pression but with the conventional BU–CY conditioning
regimen. Control patients’ characteristics are shown in
Table 1.
Liver toxicity
Liver toxicity was deﬁned by the presence of hepatic
sinusoidal obstruction syndrome (SOS) and elevation of
serum transaminases (aspartate aminotransferase and
alanine aminotransferase).3 One patient (9%) treated with
CY–BU and eight (15%) patients of the BU–CY group
developed SOS before day þ 20 after HSCT. It is
important to point out that one of the patients who
developed SOS in the CY–BU group had chronic liver
disease prior to HSCT. Alanine aminotransferase and
aspartate aminotransferase serum levels were statistically
higher in patients treated with BU–CY (P¼ 0.03) as shown
in Figure 1. Bilirubin levels were also analyzed, showing a
tendency to be higher in patients treated with BU–CY
(P¼ 0.07).
Table 1 Characteristics of patients receiving CY–BU or BU–CY
CY–BU BU–CY
No. of patients 11 51
Age (range), years 40 (21–50) 32 (14–56)
Diagnosis
MDS 3 (28%) 6 (12%)
RARS 1 (9%) 1 (2%)
RAEB 2 (19%) 4 (7%)
RAEB-t 0 1 (2%)
AML/ALL 5 (45%) 4 (8%)
1st CR 3 (27%) 2 (4%)
2nd CR 2 (18%) 2 (4%)
CML 1 (9%) 29 (57%)
Chronic phase 1 (9%) 23 (45%)
Accelerated phase 0 6 (12%)
Blast crisis 0 0
NHL 1 (9%) 3 (6%)
High-grade 2nd PR 1 (9%) 1 (2%)
Low-grade 2nd CR 0 2 (4%)
HL 0 (0%) 1 (2%)
MM 0 (0%) 1 (2%)
SAA 1 (9%) 7 (13%)
Donors
HLA-matched sibling 9 (81%) 51 (100%)
Autologous 2 (19%) 0 (0%)
Source of HSC
Peripheral blood 7 (63%) 35 (68%)
BM 4 (37%) 17 (32%)
Abbreviations: HL¼Hodgkin’s lymphoma; HSC¼hematopoietic stem
cell; MDS¼myelodysplastic syndrome; MM¼multiple myeloma;
NHL¼ non-Hodgkin’s lymphoma; RAEB¼ refractory anemia with excess
blasts; RAEB-t¼RAEB in transformation; RARS¼ refractory anemia
with ringed sideroblasts; SAA¼ severe aplastic anemia
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Engraftment
There was no engraftment failure in either group and the
median time of neutrophil engraftment was 14 days in both
the treated groups (range, 12–19 days for CY–BU and
11–22 days for BU–CY). Chimerism analysis was done by
sex-mismatched FISH technique in four patients of the
CY–BU group, showing 100% of donor chimerism on day
þ 100 post HSCT. In the BU–CY group, chimerism
analysis was done in 12 patients, showing 100% of donor
chimerism by day 100 post transplantation.
GVHD and mortality
In the CY–BU group, ﬁve (45%) patients are alive and in
CR of primary disease, in a media follow-up of 20 months
(range, 18–22). There was no relapse-related mortality.
Death causes of this group were related to GVHD and
infection. Two patients died before day þ 100, secondary
to GVHD and infection/SOS, respectively. The patient who
developed fatal SOS was the one who had chronic liver
disease before HSCT. In the BU–CY group, 26 (51%)
patients were alive and in CR, and 100-day and 1-year
TRMs were 18% and 16%, respectively. Four (44%) out of
nine patients in the CY–BU group who received allogeneic
HSCT developed grade II–IV acute GVHD,whereas two
developed extensive chronic GVHD. In the BU–CY group,
20 (39%) patients developed grade II–IV acute GVHD and
24 (47%) extensive chronic GVHD.
The myeloablative conditioning regimen BU–CY has
been widely used in patients subjected to both autologous
and allogeneic HSCT. Despite the effectiveness of this
conditioning regimen in hematologic diseases, liver toxicity
such as SOS and acute hepatocyte damage occurs in up to
40% of HSCT recipients.3 Although successful attempts at
reducing hepatic toxicity have been developed, such as
targeting BU plasma-concentration and using i.v. formul-
ation, transplant-related toxicity remains a clinical problem
to be overcome.4–6
In our cohort of patients treated with CY–BU,
signiﬁcantly less hepatic toxicity was observed and neutrophil
engraftment did not differ from that in patients treated with
BU–CY. These ﬁndings are in accordance with the data
presented by Sadeghi et al.1 in mice models supporting the
use of CY–BU in larger prospective clinical trials.
Of note, neither our patients nor the mice studied by
Sadeghi et al.1 received target BU (TBU). Therefore, we can
speculate that using CY-TBU may produce even less
toxicity while keeping its myeloablative properties.
We are aware that our limited number of patients could
have jeopardized statistical analysis in regard to incidence
of GVHD, TRM and disease-free survival. Despite this fact
we believe that our ﬁndings will encourage prospective
trials using CY–BU not only to reduce liver toxicity but
also to develop a more effective conditioning regimen.
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Figure 1 Serum AST (a), ALT (b) and bilirubin (c) of patients submitted to hematopoietic SCT (HSCT) after conditioning regimen with BU–CY (n¼ 51)
or CY–BU (n¼ 11). ALT, alanine aminotransferase; AST, aspartate aminotransferase.
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